The Antibody-mediated Rejection Market Will Grow at the Highest Pace owing to Growing Kidney Transplants

The Antibody-mediated Rejection Market Will Grow at the Highest Pace owing to Growing Kidney Transplants

The antibody-mediated rejection market comprises products such as monoclonal antibodies, assay kits, and other devices that help in detecting and preventing antibody-mediated rejection among organ transplant patients. Antibody-mediated rejection occurs when antibodies produced by the body's immune system target the transplanted kidney or other organ, causing immediate organ damage and potentially leading to transplant failure. As organ transplantation procedures are increasing worldwide along with rising cases of end-stage renal diseases, the demand for reliable diagnostic tools and therapeutics to curb post-transplant complications is growing significantly.

The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.

Key Takeaways

Key players operating in the antibody-mediated rejection market are Bristol-Myers Squibb Company, Antigen Discovery Inc., Histogen, Inc., Anthropic, Inc., and others.

The growing number of solid organ transplant procedures worldwide is a major factor driving the growth of the antibody-mediated rejection Antibody-mediated Rejection Market. As per the data by the Global Observatory on Donation and Transplantation, over 140,000 solid organ transplant procedures were performed globally in 2020.

Technological advancements in immunodiagnostic tools to detect donor-specific antibodies with improved sensitivity and specificity have increased the ability to predict rejection and graft survival after transplantation. Lucida Score by Immucor and C1qScreen by Immucor are some of the advanced diagnostic platforms available in the market.

Market Trends
Increasing research on novel and more effective therapeutics: Several biopharmaceutical companies are conducting clinical trials to evaluate new therapeutics with improved safety and efficacy such as eculizumab, bortezomib, and others for antibiotic-mediated rejection.

Potential of cell therapy: Mesenchymal stem cell therapy is being explored as a promising treatment strategy to suppress antibody production and curb rejection by modulating immune responses.

Market Opportunities
Growing transplantations in emerging economies: Regulatory approvals and governmental initiatives in developing countries will boost the adoption of therapeutic and diagnostic solutions.

Personalized diagnostic and treatment approaches: Development of donor-specific assays along with companion diagnostics for therapeutics can enable tailored management plans for individual patients.

Impact of COVID-19 on Antibody-mediated Rejection Market Growth
The COVID-19 pandemic has significantly impacted the growth of the antibody-mediated rejection market. During the initial phase of the pandemic, restrictions on non-essential medical services and travel bans led to fewer organ transplants being performed. This resulted in reduced demand for antibody-mediated rejection (AMR) therapeutics. However, with rising COVID-19 caseloads, many transplant patients were at a higher risk of severe outcomes if infected. This prompted healthcare facilities to take precautionary measures to continue delivering transplant services safely.

In the pre-COVID era, the market was growing steadily owing to the rising prevalence of AMR post-transplant. The approvals of novel immunomodulating drugs and adoption of advanced diagnostic tools were also propelling the market. However, during the pandemic, supply chain disruptions caused delays in delivering therapies to patients. Manufacturing and R&D activities of pharmaceutical companies also faced disruptions. With lockdowns now easing, transplant procedures and the demand for AMR management drugs are gradually recovering. However, the overall market growth rate for 2020 was impacted.

To mitigate future outbreak-led disruptions, healthcare stakeholders need to bolster telehealth facilities, ensure adequate stockpiles of essential drugs, and spread awareness on safe transplantation practices. Pharmacovigilance of approved therapies needs to be strengthened. More research on COVID-19's long-term effects on transplant patients is also critical to optimize their post-transplant care protocols.

Geographical Regions with Highest Value for Antibody-mediated Rejection Market
North America has traditionally been the most lucrative market for antibody-mediated rejection therapeutics, accounting for the largest revenue share. This is attributed to factors such as the rising prevalence of chronic kidney diseases, availability of advanced healthcare infrastructure, widespread medical insurance, and presence of leading market players in the region. The United States represents the single largest country market owing to its sizeable transplant recipient population and high adoption of high-cost immunomodulating drugs.

Asia Pacific is projected to be the fastest-growing regional market during the forecast period. This is mainly due to a constantly growing patient pool affected by kidney failure as a result of increasing lifestyle disease prevalence. Rising healthcare expenditures, growing public awareness, and improving access to organ transplants are supporting the market growth in Asia Pacific. Furthermore, many international drug manufacturers are targeting the Asia Pacific region to leverage the benefits of low manufacturing costs.

Fastest Growing Region for Antibody-mediated Rejection Market
Asia Pacific is expected to experience the fastest growth in the global antibody-mediated rejection market during 2019-2023. The Asia Pacific region encompasses highly populated countries such as India and China that are witnessing increased prevalence of kidney failure and liver diseases in recent years. This has led to a boom in organ transplant procedures being conducted in Asia Pacific countries. For instance, India reported a 20% increase in the number of kidney transplants between 2008 to 2018.

The region is also witnessing improved healthcare infrastructure and greater availability of affordable generic AMR drugs. Furthermore, growing medical tourism across Asia for organ transplant operations is positively influencing the market growth. Leading global pharmaceutical companies have increased their focus on the region owing to benefits such as low-cost manufacturing and regulatory approvals. The governments are also supporting market growth through funding and awareness programs. As a result of these favorable factors, Asia Pacific is anticipated to offer lucrative growth opportunities for antibody-mediated rejection therapeutics over the forecast period.

Get More Insights On- Antibody-mediated Rejection Market

Get This Report in Japanese Language: 抗体介在性拒絶反応市場

Get This Report in Korean Language: 항체 매개 거부 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)